Chrysalis BioTherapeutics, Inc.
ChrysalisBioTherapeutics, Inc. is a clinical stage biopharmaceutical company developing regenerative drugs that mimic the body´s natural signals to activate endothelial cells and stem cells to stimulate tissue repair and restore normal tissue function. Chrysalis BioTherapeutics was incorporated in Delaware in 2012 to develop innovative peptide therapeutics to save lives and improve life´ quality. Chrysalis lead drug product, TP508, was initially developed to accelerate healing of dermal and musculoskeletal injuries. TP508 proved to be especially effective in promoting healing of diabetic foot ulcers in early human clinical trials and is under development as a treatment for mass casualty injuries and unmet clinical needs including systemic effects of SARS-CoV-2.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
Chrysalis has demonstrated that TP508 mitigates effects of radiation exposure and is collaborating with US government agencies to develop TP508 as both a medical countermeasure to increase survival in case of a nuclear event and in the current pandemic, as a therapeutic to prevent COVID-19 progression, multi-organ failure, and death.
The Problem
Loss of vascular endothelial cell function and decreased capacity of stem cells to replace damaged cells lead to age-related degenerative diseases in brain and other tissues. Trauma, ionizing radiation, viral infections and uncontrolled inflammation are major causes of endothelial dysfunction and reduced stem cell activation in tissues throughout the body. These cellular effects result in vascular coagulopathies, loss of organ specific function and impaired healing. Thus, these cellular changes are at the root of many critical unmet medical needs.
The Solution
Chrysalis is pioneering therapeutic use of TP508-related drugs that harness the body’s natural regenerative signals to protect and activate vascular endothelial cells and endogenous progenitor stem cells where they exist in brain and other tissues throughout the body. Extensive research has shown that injection of TP508 safely restores endothelial function and activates normal stem cells to initiate tissue regeneration and overcome effects of trauma, ischemia, age-related degenerative disease, and radiation-induced tissue damage. These effects of TP508 are expected to mitigate systemic effects of SARS-CoV-2 including post-disease myocardial and neurological effects.
Mission Statement
Chrysalis is committed to develop and commercialize safe and effective drugs that utilize natural regenerative processes to save lives, improve quality of life, and provide therapeutic solutions for current and future unmet medical needs.
Vision for the Future
Chrysalis aims to become the global leader in mitigating normal tissue damage induced by trauma, chronic degenerative disease, viral infection and ionizing radiation encountered during radiation therapy, accidental exposure, or a nuclear event. Use of TP508-related drugs will change the practice of medicine and provide outcome-changing solutions for treatment of neurocognitive decline caused by neuro-trauma and neurodegenerative disease. TP508 treatment will save lives and improve life quality for adults and children and where failure to intervene may have life-long physical, behavioral or psychological effects.